Vident Advisory’s GSK GSK Stock Holding History

Vident Advisory’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99M	Buy	37,908 +925	+3%	+$48.9K	0.01%	692
2026 Q1	$2.04M	Buy	36,983 +9,064	+32%	+$491K	0.02%	620
2025 Q4	$1.37M	Buy	27,919 +689	+3%	+$32.1K	0.01%	690
2025 Q3	$1.18M	Sell	27,230 -287	-1%	-$11.2K	0.01%	752
2025 Q2	$1.06M	Sell	27,517 -857	-3%	-$32.7K	0.01%	716
2025 Q1	$1.1M	Buy	28,374 +8,294	+41%	+$304K	0.02%	691
2024 Q4	$679K	Buy	20,080 +813	+4%	+$29.3K	0.01%	811
2024 Q3	$788K	Buy	19,267 +1,735	+10%	+$71K	0.02%	722
2024 Q2	$675K	Buy	17,532 +5,698	+48%	+$240K	0.02%	745
2024 Q1	$507K	Buy	11,834 +1,173	+11%	+$48.4K	0.01%	820
2023 Q4	$395K	Buy	10,661 +971	+10%	+$34.9K	0.01%	887
2023 Q3	$351K	Buy	+9,690	New	+$344K	0.01%	828

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vident Advisory's GSK Position: Q2 2026 in Review

Vident Advisory increased its GSK (GSK) stake by 2.5% in Q2 2026, buying an estimated $48.9K and bringing the position to 37,908 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #692.

Vident Advisory first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.04M in Q1 2026. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Vident Advisory held 37,908 shares of GSK worth $1.99M as of Q2 2026.
Vident Advisory bought 925 GSK shares in Q2 2026, an estimated $48.9K.
GSK made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #692 holding.
Vident Advisory first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's GSK position peaked at $2.04M in Q1 2026.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.